NIH funds in‑body CRISPR delivery advance
- The National Institutes of Health said on April 13 that a UT Austin-led team found a compact CRISPR enzyme, Al3Cas12f, and engineered it for targeted delivery inside the body. - The engineered version, Al3Cas12f RKK, raised editing efficiency from under 10% to above 80% across tested human-cell targets, with one commonly edited genomic site reaching 90%. - The work targets a delivery bottleneck that has kept many CRISPR therapies outside the body, while NIH’s SCGE program is funding tissue-targeted translation efforts. (nih.gov)
CRISPR is a gene-editing tool, but getting it to the right cells inside the body has been one of the field’s hardest delivery problems. On April 13, the National Institutes of Health said a UT Austin-led team had built a smaller editor aimed at that bottleneck. (nih.gov) Most CRISPR systems work like molecular scissors guided to a DNA address, but the protein is often too large to fit into targeted delivery vehicles. NIH said that size limit has pushed many clinical uses toward editing cells outside the body, then reinfusing them. (nih.gov) The new enzyme is called Al3Cas12f, a naturally occurring miniature nuclease identified through metagenomics by researchers at the University of Texas at Austin. Its compact size makes it compatible with adeno-associated virus, or AAV, a common gene-therapy delivery vector. (nih.gov) (nature.com) The team then engineered a variant called Al3Cas12f RKK. NIH said it lifted editing efficiency from less than 10% to more than 80% across tested targets in human cells, and to 90% at one commonly edited genomic region. (nih.gov) (nature.com) Researchers used imaging and machine learning to study why the enzyme worked. David Taylor, a molecular biosciences professor at UT Austin, said the protein forms a more stable complex than similar small editors, helping it function in human cells. (nih.gov) (utexas.edu) NIH linked the targeted genes in the experiments to cancer, atherosclerosis and amyotrophic lateral sclerosis, or ALS. The agency said the next step is to package the editor into AAV and test how it performs as an in-body therapy. (nih.gov) That next step lines up with a broader NIH effort. The Common Fund’s Somatic Cell Genome Editing program says its second phase, running from fiscal 2023 through 2027, is focused on targeted delivery technologies and moving genome-editing therapies toward clinical trials. (commonfund.nih.gov) NIH says the program’s first phase, from fiscal 2018 through 2023, built delivery systems with greater tissue specificity for organs including the brain, ear, heart and lung. Its funded projects now include AAV-mediated editing for inherited hearing loss and platform work for in vivo and ex vivo sickle-cell therapies. (commonfund.nih.gov 1) (commonfund.nih.gov 2) The same program has also backed prize and grant mechanisms aimed at “targeted genome editor delivery” and at studies needed before human trials. Those listings place the new compact editor inside a larger federal push to make direct, tissue-specific editing practical. (commonfund.nih.gov) For now, the April 2026 result is still a lab-stage advance in human cells, not a treatment. But it addresses the size constraint that has kept many CRISPR medicines tied to cell harvesting and ex vivo manufacturing. (nih.gov)
